Combination of anti-angiogenic therapy and virotherapy: Arming oncolytic viruses with anti-angiogenic genes

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 6, 2009, Pages 664-669

  Tysome, James R ^a   Lemoine, Nick R ^a,b   Wang, Yaohe ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Angiostatin; Anti angiogenesis; Endostatin; IL 12; Virotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CANSTATIN; ENDOSTATIN; INTERLEUKIN 12; ONCOLYTIC VIRUS; ONYX 015; PROTEIN TYROSINE KINASE INHIBITOR; RETINA S ANTIGEN; THROMBOCYTE FACTOR 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; VACCINIA VACCINE; VASCULOTROPIN; VIROTHERAPY AGENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; CANCER RESEARCH; COLON CANCER; CYTOLYSIS; ENZYME ACTIVITY; GENETIC ENGINEERING; KRINGLE DOMAIN; MICROENVIRONMENT; NONHUMAN; PROTEIN TARGETING; REVIEW; TUMOR XENOGRAFT; VIROTHERAPY; VIRUS REPLICATION; WILD TYPE;

ANGIOGENESIS INHIBITORS; CHEMOKINES; COMBINED MODALITY THERAPY; FIBROBLAST GROWTH FACTORS; HUMANS; INTERLEUKINS; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIRUSES; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 72449155623     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med (1971) 285(21):1182-1186.
2. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 29(6 Suppl 16):15-18.
3. Sessa C, Guibal A, Del Conte G, Ruegg C: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: Tools or decorations? Nat Clin Pract Oncol (2008) 5(7):378-391.
4. Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY, Tang ZM: Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin (2005) 26(1):124-128.
5. Tysome J, Briat A, Alusi G, Cao F, Gao D, Yu J, Wang P, Yang S, Dong Z, Wang S, Deng L et al: Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther (2009) 16(10):1223-1233.
6. Tandle A, Blazer DG 3rd, Libutti SK: Antiangiogenic gene therapy of cancer: Recent developments. J Transl Med (2004) 2(1):22.
7. Dome B, Dobos J, Tovari J, Paku S, Kovacs G, Ostoros G, Timar J: Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A (2008) 73(3):186-193.
8. Li WW, Hutnik M, Gehr G: Antiangiogenesis in haematological malignancies. Br J Haematol (2008) 143(5):622-631.
9. Ma J, Waxman DJ: Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 7(12):3670-3684.
10. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390(6658):404-407.
11. Kirn DH, Thorne SH: Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 9(1):64-71.
12. Parato KA, Senger D, Forsyth PA, Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 5(12):965-976.
13. Liu TC, Galanis E, Kirn D: Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 4(2):101-117.
14. Garber K: China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst (2006) 98(5):298-300.
15. Liu TC, Kirn D: Gene therapy progress and prospects cancer: Oncolytic viruses. Gene Ther (2008) 15(12):877-884.
16. Dvorak HF: Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315(26):1650-1659.
17. Aghi M, Rabkin SD, Martuza RL: Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res (2007) 67(2):440-444.
18. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B: Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 99(23):1768-1781.
19. Zhang Z, Zou W, Wang J, Gu J, Dang Y, Li B, Zhao L, Qian C, Qian Q, Liu X: Suppression of tumor growth by oncolytic adenovirusmediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther (2005) 11(4):553-562.
20. Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ: Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol Ther (2006) 13(5):938-946.
21. Kang YA, Shin HC, Yoo JY, Kim JH, Kim JS, Yun CO: Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Mol Ther (2008) 16(6):1033-1040.
22. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD: Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res (2006) 12(22):6791-6799.
23. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev (2001) 12(4):375-391.
24. Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA, Kim H, Yun CO: Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: Effects on antiangiogenesis and tumor growth inhibition. Gene Ther (2008) 15(9):635-651.
25. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med (1993) 178(4):1223-1230.
26. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science (1990) 247(4938):77-79.
27. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther (2006) 13(3):253-265.
28. Wong RJ, Chan MK, Yu Z, Ghossein RA, Ngai I, Adusumilli PS, Stiles BM, Shah JP, Singh B, Fong Y: Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res (2004) 10(13):4509-4516.
29. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A: Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther (2006) 14(6):789-797.
30. Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, Hay JG: Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther (2007) 15(11):1982-1990.
31. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 66(5):2509-2513.
32. Ahonen M, Baker AH, Kahari VM: Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res (1998) 58(11):2310-2315.
33. Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA et al: Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res (2005) 65(20):9398-9405.
34. Bond M, Murphy G, Bennett MR, Newby AC, Baker AH: Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem (2002) 277(16):13787-13795.
35. Wilson RF, Morse MA, Pei P, Renner RJ, Schuller DE, Robertson FM, Mallery SR: Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res (2003) 23(2B):1289-1295.
36. Folkman J: Endogenous angiogenesis inhibitors. Apmis (2004) 112(7-8):496-507.
37. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM et al: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2002) 20(18):3792-3803.
38. Li G, Sham J, Yang J, Su C, Xue H, Chua D, Sun L, Zhang Q, Cui Z, Wu M, Qian Q: Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int J Cancer (2005) 113(4):640-648.
39. Su C, Na M, Chen J, Wang X, Liu Y, Wang W, Zhang Q, Li L, Long J, Liu X, Wu M et al: Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Mol Cancer Res (2008) 6(4):568-575.
40. Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D, Wang W, Cui Z, Liu Y, Liu C, Jiang M et al: Effective gene-viral therapy for telomerasepositive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res (2004) 64(15):5390-5397.
41. Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM, Tanabe KK: Oncolysis by viral replication and inhibition of angiogenesis by a replicationconditional herpes simplex virus that expresses mouse endostatin. Cancer (2004) 101(4):869-877.
42. Scappaticci FA, Contreras A, Smith R, Bonhoure L, Lum B, Cao Y, Engleman EG, Nolan GP: Statin-AE: A novel angiostatinendostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis (2001) 4(4):263-268.
43. Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C: Prostaterestricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res (2008) 14(1):291-299.
44. Yang CT, Lin YC, Lin CL, Lu J, Bu X, Tsai YH, Jia WW: Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res (2005) 25(3B):2049-2054.
45. Hiley CT, Yuan M, Lemoine NR, Wang Y: Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther (2009):doi:10.1038/gt.2009.132.
46. Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J, Kisker O: Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res (2005) 65(23): 11044-11050.
47. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ: Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res (2004) 10(1 Pt 1):33-42.
48. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M: Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem (1997) 272(36):22924-22928.
49. Fan JK, Xiao T, Gu JF, Wei N, He LF, Ding M, Liu XY: Increased suppression of oncolytic adenovirus carrying mutant k5 on colorectal tumor. Biochem Biophys Res Commun (2008) 374(2):198-203.
50. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R: Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: A potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med (2007) 4(9):491-502.